Last week at MalariaWorld...how to get your tool to become mainstream
Last week I pondered over what it is that makes new tools or technologies become mainstream in malaria control and elimination. Read the editorial here. Regretfully, I could not come up with a clear answer, but maybe you can - we welcome your comments.
As scientists we deliver new knowledge on malaria, but what is it that makes new inventions become mainstream? That's the question I am struggling with. And, do you consider it (also) our task to make sure that our new inventions are taken up by those practicing malaria control? Are we responsible for the valorisation of our own work?
I am curious how you think about this...
Bart
Enjoy this week's MalariaWorld - the MW team.
Calais Document Category:
The study suggests that pvrbp-2 is highly polymorphic genetic marker which can be used for population genetic analyses. RFLP analysis suggests presence of nearly similar proportion of Sal-1 and Belem alleles in Indian P. vivax populations. 
The aim of this study was to evaluate the larvicidal activity of a genetically engineered cyanobacterium, Anabaena PCC 7120#11, against five African Anopheles species in laboratory bioassays.
This is the first study to implicate that the active induction of antigen-specific CD8+ T cells should be included in the development of a vaccine against MBS.
Recent evidence demonstrates that it is the interplay between CD4+ and CD8+ T cells, and the regulation of their response, throughout infection that dictates immunity and the pathogenesis of malaria.